PTC Company Profile (NASDAQ:PMTC)


PTC logoPTC Inc. is a global computer software and services company. The Company offers a portfolio of computer-aided design (CAD) modeling, product lifecycle management (PLM) and service lifecycle management (SLM) solutions for manufacturers to create, operate, and service products. It offers a suite of Internet of Things (IoT) solutions that enables its customers to connect, manage and analyze data, and create applications. Its segments include the Solutions Group, the IoT Group and Professional Services. The Solutions Group segment includes its CAD, PLM and SLM products. The IoT Group segment includes its IoT, analytics and augmented reality (AR) solutions. The Professional Services segment includes consulting, implementation and training business. Its IoT products include ThingWorx, KEPServerEX, Vuforia Studio and Vuforia. Its CAD products include Creo and Mathcad. Its PLM products include Windchill, Integrity, Navigate and Creo View. Its SLM products include Servigistics and Arbortext.

Industry, Sector and Symbol:
  • Sector: Technology
  • Industry: Application Software
  • Sub-Industry: Application Software
  • Symbol: NASDAQ:PMTC
  • CUSIP: 69370C10
  • Web:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 14.35
  • P/E Growth: N/A
  • Dividend Yield: 1.0%
  • Net Margins: -0.33%
  • Return on Equity: -0.45%
  • Return on Assets: -0.16%

Frequently Asked Questions for PTC (NASDAQ:PMTC)

What is PTC's stock symbol?

PTC trades on the NASDAQ under the ticker symbol "PMTC."

Where is PTC's stock going? Where will PTC's stock price be in 2017?

1 equities research analysts have issued twelve-month price objectives for PTC's shares. Their predictions range from $57.00 to $57.00. On average, they expect PTC's share price to reach $57.00 in the next year. View Analyst Ratings for PTC.

Who are some of PTC's key competitors?

Who are PTC's key executives?

PTC's management team includes the folowing people:

  • Robert P. Schechter, Independent Chairman of the Board
  • James E. Heppelmann, President, Chief Executive Officer, Director
  • Andrew D. Miller CPA, Chief Financial Officer, Executive Vice President
  • Robert C. Gremley, Group President - Technology Platform Group
  • Craig Hayman, Chief Operating Officer, Group President - Solutions Group
  • Barry F. Cohen, Executive Vice President - Strategy
  • Matthew Cohen, Executive Vice President - Global Services
  • Anthony DiBona, Executive Vice President - Global Support
  • Aaron C. Von Staats, Corporate Vice President, General Counsel, Secretary
  • Corinna Lathan, Director

How do I buy PTC stock?

Shares of PTC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PTC's stock price today?

One share of PTC stock can currently be purchased for approximately $32.58.

MarketBeat Community Rating for PTC (NASDAQ PMTC)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about PTC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for PTC (NASDAQ:PMTC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $57.00 (74.95% upside)
Consensus Price Target History for PTC (NASDAQ:PMTC)
Price Target History for PTC (NASDAQ:PMTC)
Analysts' Ratings History for PTC (NASDAQ:PMTC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017WedbushReiterated RatingOutperform$57.00N/AView Rating Details
11/26/2015Jefferies Group LLCLower Price TargetBuy$33.00 -> $25.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for PTC (NASDAQ:PMTC)
Earnings by Quarter for PTC (NASDAQ:PMTC)
Earnings History by Quarter for PTC (NASDAQ PMTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2013Q413$0.53$0.59$335.00 million$344.80 millionViewN/AView Earnings Details
7/24/2013Q3 2013$0.43$0.45$322.52 million$315.50 millionViewN/AView Earnings Details
4/24/2013Q2 2013$0.35$0.41$315.92 million$313.90 millionViewN/AView Earnings Details
1/23/2013Q1 2013$0.33$0.36$320.89 million$321.30 millionViewN/AView Earnings Details
10/31/2012Q412$0.48$0.50$330.78 million$325.00 millionViewN/AView Earnings Details
7/25/2012$0.30$0.37ViewN/AView Earnings Details
4/25/2012$0.27$0.30ViewN/AView Earnings Details
10/26/2011$0.43$0.47ViewN/AView Earnings Details
4/27/2011$0.25$0.26ViewN/AView Earnings Details
1/26/2011$0.26$0.22ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for PTC (NASDAQ:PMTC)
Current Year EPS Consensus Estimate: $2.03 EPS
Next Year EPS Consensus Estimate: $2.27 EPS


Dividend History for PTC (NASDAQ:PMTC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for PTC (NASDAQ:PMTC)
Insider Trades by Quarter for PTC (NASDAQ:PMTC)
Insider Trades by Quarter for PTC (NASDAQ:PMTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/18/2013Anthony DibonaEVPSell23,457$32.03$751,327.71View SEC Filing  
11/12/2013James HeppelmannCEOSell25,000$32.06$801,500.00View SEC Filing  
8/13/2013Barry CohenEVPSell59,999$28.08$1,684,771.92View SEC Filing  
8/5/2013Anthony DibonaEVPSell8,751$27.53$240,915.03View SEC Filing  
8/1/2013James E HeppelmannCEOSell39,999$27.77$1,110,772.23View SEC Filing  
8/1/2013Robert RanaldiEVPSell4,000$27.78$111,120.00View SEC Filing  
7/30/2013Marc DiouaneEVPSell11,126$26.73$297,397.98View SEC Filing  
5/10/2013Marc DiouaneEVPSell7,375$24.07$177,516.25View SEC Filing  
5/1/2013James E HeppelmannCEOSell40,000$23.61$944,400.00View SEC Filing  
5/1/2013Robert RanaldiEVPSell4,000$23.62$94,480.00View SEC Filing  
12/4/2012Donald K GriersonDirectorSell10,000$20.10$201,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for PTC (NASDAQ:PMTC)
Latest Headlines for PTC (NASDAQ:PMTC)
DateHeadline logoPTC Therapeutics earns $20M milestone from Roche on advancement of SMA candidate RG7916; shares up 1% - October 12 at 9:50 AM logoIs The Likelihood Of An FDA Complete Response Letter Fully Priced In To PTC Therapeutics? - October 9 at 2:55 PM logoPTC Inc (PMTC) Receives "Outperform" Rating from Wedbush - October 5 at 7:34 PM logoU.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely' - September 29 at 2:37 PM logoPTC rollercoaster, shares up almost 40% from Tuesday low - September 29 at 11:40 AM logoInvestors shaken by PTC's briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14% premarket - September 26 at 9:55 AM logoContrasting PTC (PMTC) & Great Elm Capital Group (GEC) - September 22 at 4:26 PM logoInteractive Intelligence Group (ININ) vs. PTC (PMTC) Head to Head Contrast - September 17 at 12:34 PM logoContrasting PTC (PMTC) & Radware (RDWR) - September 11 at 2:24 AM logoContrasting PTC (NASDAQ:PMTC) and SeaChange International (SEAC) - August 13 at 10:32 PM logoPTC's (PMTC) "Outperform" Rating Reaffirmed at Wedbush - July 20 at 11:46 AM logoPortola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma - June 15 at 8:52 AM logoPTC Therapeutics sees Emflaza net price of $35K annually per patient - May 8 at 2:31 PM logoPTC Therapeutics CFO to exit - April 10 at 4:25 PM logoWhy PTC Therapeutics Dropped 25.3% in March - April 7 at 8:47 AM logoWhy PTC's Revenue Still Raises Eyebrows - March 26 at 10:27 AM logoA Deep Forensic Analysis Of PTC Provides Evidence Suggesting Misrepresentations And 50% - 60% Downside - March 24 at 1:23 AM logoA Deep Forensic Analysis Of PTC Provides Evidence Suggesting Misrepresentations And 50- 60% Downside - March 23 at 3:16 PM logoWhy PTC Therapeutics, Tellurian, and B&G Foods Slumped Today - March 16 at 5:03 PM logoFDA to review PTC's marketing application for DMD candidate Translarna under protest regulations; action date October 24; shares ahead 15% premarket - March 6 at 8:57 AM logoBad News Biotechs: What's Next for Juno and PTC Therapeutics? - March 4 at 6:51 AM logoWhy PTC Therapeutics Is Plunging Today - March 2 at 1:52 PM logoNicox announces the presentation of NCX 667 scientific data at AOPT 2017 - February 21 at 4:36 AM logoPTC's Revenue Puzzle Still Unsolved - January 19 at 5:04 PM logoPTC's Translarna approved in Europe for another year - January 9 at 8:41 PM logoPTC Therapeutics, Inc. in 3 Charts - December 7 at 4:43 PM logoWhy PTC Therapeutics, Inc. Stock Rose 75.4% in November - December 5 at 2:27 PM logoWhat PTC Therapeutics' CFO Is Saying About Translarna's Conditional Approval - November 12 at 7:48 AM logoMid-Afternoon Market Update: Gold Futures Down 3.5%; PTC Therapeutics Shares Spike Higher - November 11 at 3:19 PM logoWhy PTC Therapeutics Is Rocketing 74% Today - November 11 at 1:31 PM logoEuropean advisory committee backs renewal of marketing authorization for PTC's Translarna; shares up 78% premarket - November 11 at 9:38 AM logoPTC Therapeutics Surges 88% On European Marketing Authorization - November 11 at 9:19 AM logoA Trust-Me Story at Software Maker PTC - November 1 at 1:46 PM logoPTC misses by $0.10, misses on revenue - October 26 at 4:48 PM logoNew Sales Model Obscures Weakness at Software Maker - October 25 at 6:14 PM logoPTC Therapeutics poised for $20M milestone from licensee Roche on advancement of mid-stage study of RG7916 in spinal muscular atrophy; shares ahead 4% premarket - October 21 at 9:20 AM logoWhy LendingClub Corp (LC), Devon Energy Corp (DVN) and PTC Therapeutics, Inc. (PTCT) Are 3 of Today’s Worst Stocks - October 17 at 4:40 PM logoWhy PTC Therapeutics, Inc. Is Crashing Today - October 17 at 1:55 PM logoMid-Day Market Update: Hasbro Gains On Earnings Beat; PTC Therapeutics Shares Slide - October 17 at 12:54 PM logoPTC Therapeutics presents ataluren data in DMD; shares inch up 2% - October 6 at 10:19 AM logoPTC Therapeutics up 17% on licensee Roche's move into mid-stage study in spinal muscular dystrophy - September 30 at 2:01 PM logoWhy PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday - September 20 at 4:19 PM logoWhy PTC Therapeutics Shares Skyrocketed 20.6% Today - September 19 at 9:06 PM logoHottest Manufacturing Stocks Now – SRPT TANH SORL PTCT - September 19 at 11:58 AM logo3D Systems introduces path to production, PTC partnership - September 12 at 1:01 PM logoWhy PTC Therapeutics Shares Skyrocketed 27% Today - August 5 at 4:43 PM logoRegulatory review of PTC's Translarna marketing authorization in Europe delayed, renewal expected; shares off 5% - July 25 at 11:55 AM logoPTC Therapeutics up 14% premarket on Translarna deal with England's NHS - July 7 at 9:54 AM logoWhy PTC Therapeutics Jumped 10% In May - June 9 at 6:27 PM logoSarepta buying spreads out to PTC Therapeutics; shares up 5% premarket - May 25 at 8:43 AM



PTC (PMTC) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.